Human models for COVID‐19 research
Maximillian Woodall, Tereza Masonou, Katie‐Marie Case, Claire M. Smith
Abstract
Currently, therapeutics for COVID-19 are limited. To overcome this, it is important that we use physiologically relevant models to reproduce the pathology of infection and evaluate the efficacy of antiviral drugs. Models of airway infection, including the use of a human infection challenge model or well-defined, disease relevant in vitro systems can help determine the key components that perpetuate the severity of the disease. Here, we briefly review the human models that are currently being used in COVID-19 research and drug development.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDrug developmentDiseaseHuman diseaseIntensive care medicineMedicineComputational biologyDrugVirologyBiologyInfectious disease (medical specialty)PathologyPharmacologyOutbreakCOVID-19 Clinical Research StudiesRespiratory viral infections researchSARS-CoV-2 and COVID-19 Research